• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Puma Biotechnology, Inc.

< Previous 1 2 3 Next >
Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
August 08, 2023
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Second Quarter Financial Results
August 03, 2023
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results
July 20, 2023
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2023
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting
June 04, 2023
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
May 05, 2023
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports First Quarter Financial Results
May 04, 2023
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results
April 20, 2023
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
April 11, 2023
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology
March 14, 2023
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
March 03, 2023
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
March 02, 2023
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Participate in a Panel Discussion at Cowen’s 43rd Annual Health Care Conference
February 28, 2023
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
February 16, 2023
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2023
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation
February 01, 2023
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Present at B. Riley Securities’ 3rd Annual Oncology Conference
January 12, 2023
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
January 11, 2023
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Releases Updated Corporate Presentation
January 09, 2023
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium
December 07, 2022
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2022
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Third Quarter 2022 Financial Results
November 03, 2022
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
November 02, 2022
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
October 27, 2022
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
October 20, 2022
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2022
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor
September 20, 2022
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022
September 11, 2022
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2022
From Puma Biotechnology, Inc.
Via Business Wire
Tickers PBYI
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap